Table 3. Descriptive data and reliability coefficients of the three dimensions of participants’ attitudes towards the BRCA1/2 genetic testing scale–(InCRisC France, n = 659).
| Subscale 1 Anxiety-conflict and discrimination |
Subscale 2 Risk Information |
Subscale 3 Prevention-Surveillance |
Overall scale Attitudes Towards Gene Testing for BRCA1/2 |
|
|---|---|---|---|---|
| Cronbach’s alpha | 0.79 | 0.76 | 0.62 | 0.73 |
| Score (mean ± SD) | 59.67±19.39 | 72.86±16.28 | 75.35±14.56 | 57.22±11.92 |
| Median Value | 62.5 | 75.0 | 75.0 | 56.8 |
| Possible score range | 0–100 | 0–100 | 0–100 | 0–100 |
| Observed score range | 0–100 | 18.8–100 | 12.5–100 | 19.8.3–95.3 |
| Floor n (%) | 2 (0.30) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Ceiling, n (%) | 10 (1.52) | 80 (12.14) | 44 (6.68) | 0 (0.00) |
| The expected health benefits of BRCA1 and BRCA2 testing exceed anticipated negative consequences by a sufficiently wide margin to justify prescribing the test: | mean (SD) | mean (SD) | mean (SD) | mean (SD) |
| Strongly disagree / Disagree | 69.31 (19.03) | 61.80 (19.69) | 67.52 (17.54) | 47.67 (12.91) |
| Agree | 60.00 (17.94) | 71.03 (15.05) | 73.32 (13.35) | 56.09 (10.65) |
| Strongly agree | 55.61 (21.04) | 80.02 (14.30) | 82.12 (12.70) | 62.73 (11.16) |
| P-value | <0.001 | <0.001 | <0.001 | <0.001 |